Significance of decoy receptor 3 (Dcr3) and external-signal regulated kinase 1/2 (Erk1/2) in gastric cancer

BMC Immunology

Volumn 13, Issue , 2012, Pages

  Yang, Donghai ^a   Fan, Xin ^a   Yin, Ping ^a   Wen, Qiang ^a   Yan, Feng ^a   Yuan, Sibo ^a   Liu, Bin ^a   Zhuang, Guohong ^a   Liu, Zhongchen ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DECOY RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STAGING; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM STAGING; NEOPLASM TRANSPLANTATION; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; STOMACH NEOPLASMS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84861828000     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-13-28     Document Type: Article

References (22)

1. Pitti RM, Marsters SA, Lawrence DA, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998, 396:699-703. 10.1038/25387, 9872321.
2. Yu KY, Kwon B, Ni J, et al. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999, 274:13733-13736. 10.1074/jbc.274.20.13733, 10318773.
3. Migone TS, Zhang J, Luo X, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002, 16:479-492. 10.1016/S1074-7613(02)00283-2, 11911831.
4. Roth W, Isenmann S, Nakamura M, et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 2001, 61:2759-2765.
5. Bai C, Connolly B, Metzker ML, et al. Overexpreasion of M68P DcB3 human gastrointestinal tract tumors independent of gene amplification and its location in a fourgene cluster. Proc Natl Acad Sci USA 2000, 97(3):1230-1235. 10.1073/pnas.97.3.1230, 15578, 10655513.
6. Shoichiro TSUJI, Ryo H, Shin Y, et al. Endogenous Decoy Receptor 3 Blocks The Growth Inhibition Signals Mediated by Fas Ligand in Human Pancreatic Adenocarcinoma. Int J Cancer 2003, 106:17-25. 10.1002/ijc.11170, 12794752.
7. Yulian WU, Bing H, Hongwei S, et al. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer 2003, 105:724-732. 10.1002/ijc.11138, 12740925.
8. Wu Y, Guo E, Yu J, et al. High DcR3 expression predicts stage pN2 in gastric cancer. Hepatogastroenterology. 2007, 54(79):2172-2176.
9. Jiangning W. Expression of ERK1/2 protein in cholangiocarcinoma relation with TNM stages. Shandong medicine. 2008, 48(14):60-61.
10. Kim S, Fotladu A, Kotoula V. Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia. Clini immunol. 2005, 115(3):286-294.
11. Yang CR, Wang JH, Hsieh SL, et al. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. Cell death differ. 2004, 11(Suppl 1):S97-S107.
12. Yu KY, Kwon B, Ni J. A newly identified member of tumor necrosis factor receptor super family (TR6) suppresses LIGHT-mediated apoptosis. T Biol Chem 1999, 274(20):13733-13736.
13. Takahama Y, Yamada Y, Emoto K, et al. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 2002, 5(2):61-68. 10.1007/s101200200011, 12111580.
14. Lin W, Hsieh SL. Decoy receptor 3: A pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol 2011, 81(7):838-847. 10.1016/j.bcp.2011.01.011, 21295012.
15. Hornberg JJ, Bernd B, Bruggeman FJ, Birgit S, Reinhart H, Westerhoff HV. Control of MAPK signalling: from complexity to what really matters. Oncogene 2005, 24:5533-5542. 10.1038/sj.onc.1208817, 16007170.
16. Kondoh K, Torii S, Nishida E. Control of MAP kinase signaling to the nucleus. Chromosoma 2005, 114:86-91. 10.1007/s00412-005-0341-9, 15902482.
17. Schmitz KJ, Wohlschlaeger J, Alakus H, et al. Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations. Virchows Arch. 2007, 450:151-159. 10.1007/s00428-006-0342-y, 17149612.
18. Hayashi S, Nishiyama T, Miura Y. DcR3 induces cell proliferation through MAPK signaling in chondrocytes of osteoarthritis. Osteoarthr Cartil 2011, 19(7):903-910. 10.1016/j.joca.2011.03.005, 21420502.
19. Chen G, Luo D, Wang Y, Liao Z, Zhang M. DcR3 suppresses apoptosis of tumor cells in HCC. Chinese Journal of Net Pathology 2007, 36(2):113-117.
20. Yang H, Qu L, Ma H. Mycoplasma hyorhinis infection in gastric carcinoma and its effects on the malignant phenotypes of gastric cancer cells. BMC Gastroenterol 2010, 10(1):132. 10.1186/1471-230X-10-132, 2993648, 21062494.
21. Xi L, Xiao C, Bandsma RH. C-reactive protein impairs hepatic insulin sensitivity and insulin signaling in rats: Role of mitogen-activated protein kinases. Hepatology 2011, 53(1):127-135. 2010 Sep; 24. [Epub ahead of print] 2011 Jan, 10.1002/hep.24011, 20967757.
22. Tu HF, Liu CJ, Liu SY. Serum Decoy receptor 3 level:a predictive marker for nodal metastasis and survival among oral cavity cancer patients. Head and neck-journal for sciences and specialties of the head and neck 2011, 33(3):396-402.